Veterinary Pharmaceuticals Market by Product (Drugs, mAbs, Immunomodulators, Medicated Feed Additives), Route of Administration, Formulation Type, Indication, Animal Type (Companion, Livestock), Distribution Channel, End User-Global Forecast to 2031

1 INTRODUCTION 40 1.1 STUDY OBJECTIVES 40 1.2 MARKET DEFINITION 41 1.2.1 INCLUSIONS AND EXCLUSIONS 41 1.3 MARKET SCOPE 42 1.3.1 MARKETS COVERED 42 1.3.2 YEARS CONSIDERED 43 1.4 CURRENCY CONSIDERED 43 1.5 STAKEHOLDERS 44 2 EXECUTIVE SUMMARY 45 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 45 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 46 2.3 DISRUPTIVE TRENDS IN VETERINARY PHARMACEUTICALS MARKET 47 2.4 HIGH-GROWTH SEGMENTS 48 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 49 3 PREMIUM INSIGHTS 50 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY PHARMACEUTICALS MARKET 50 3.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE AND COUNTRY 51 3.3 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52 3.4 VETERINARY PHARMACEUTICALS MARKET: DEVELOPING VS. DEVELOPED ECONOMIES, 2026−2031 52 4 MARKET OVERVIEW 53 4.1 INTRODUCTION 53 4.2 MARKET DYNAMICS 53 4.2.1 DRIVERS 54 4.2.1.1 Rising companion animal ownership and pet humanization 54 4.2.1.2 Growing prevalence of infectious and dermatological diseases in animals 56 4.2.1.3 Increasing demand for animal-derived food products 57 4.2.2 RESTRAINTS 59 4.2.2.1 Growing concerns over antimicrobial resistance (AMR) 59 4.2.2.2 Stringent regulatory approval processes for veterinary drugs 59 4.2.3 OPPORTUNITIES 60 4.2.3.1 Rising demand for parasiticides and dermatology products 60 4.2.3.2 Growth potential in rural and low-income regions 60 4.2.4 CHALLENGES 61 4.2.4.1 Monitoring drug residues in food-producing animals 61 4.2.4.2 Balancing animal welfare, productivity, and compliance requirements 61 4.3 UNMET NEEDS AND WHITE SPACES 62 4.4 INTERCONNECTED MARKET AND CROSS-SECTOR OPPORTUNITIES 63 4.4.1 INTERCONNECTED MARKETS 63 4.4.2 CROSS-SECTOR OPPORTUNITIES 64 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64 5 INDUSTRY TRENDS 65 5.1 PORTER’S FIVE FORCES ANALYSIS 65 5.1.1 THREAT OF NEW ENTRANTS 66 5.1.2 THREAT OF SUBSTITUTES 66 5.1.3 BARGAINING POWER OF SUPPLIERS 66 5.1.4 BARGAINING POWER OF BUYERS 66 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67 5.2 MACROECONOMICS INDICATORS 67 5.2.1 INTRODUCTION 67 5.2.2 GDP TRENDS AND FORECAST 67 5.2.3 TRENDS IN GLOBAL ANIMAL HEALTHCARE INDUSTRY 68 5.2.4 TRENDS IN GLOBAL VETERINARY PHARMACEUTICALS INDUSTRY 70 5.3 VALUE CHAIN ANALYSIS 70 5.4 SUPPLY CHAIN ANALYSIS 71 5.5 ECOSYSTEM ANALYSIS 72 5.6 PRICING ANALYSIS 73 5.6.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025 73 5.6.2 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025 75 5.6.3 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 75 5.7 TRADE ANALYSIS 76 5.7.1 IMPORT DATA FOR HS CODE 30, 2021–2024 77 5.7.1.1 Import scenario (HS code 30) 77 5.7.2 EXPORT DATA FOR HS CODE 30, 2021–2024 77 5.7.3 EXPORT SCENARIO (HS CODE 30) 78 5.8 KEY CONFERENCES AND EVENTS IN 2026–2027 78 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79 5.10 INVESTMENT AND FUNDING SCENARIO 80 5.11 CASE STUDY ANALYSIS 80 5.11.1 ZOETIS INC. 80 5.11.2 BOEHRINGER INGELHEIM ANIMAL HEALTH 81 5.11.3 MERCK ANIMAL HEALTH 81 5.11.4 ELANCO ANIMAL HEALTH 81 5.11.5 CEVA SANTE ANIMALE 82 5.12 IMPACT OF 2025 US TARIFF - VETERINARY PHARMACEUTICALS MARKET 82 5.12.1 INTRODUCTION 82 5.12.2 KEY TARIFF RATES 83 5.12.3 PRICE IMPACT ANALYSIS 83 5.12.4 IMPACT ON REGIONS 83 5.12.4.1 North America 83 5.12.4.2 Europe 84 5.12.4.3 Asia Pacific 84 5.12.5 IMPACT ON END-USE INDUSTRIES 84 5.12.5.1 Veterinary hospitals & clinics 84 5.12.5.2 Home care settings 84 5.12.5.3 Livestock farms 84 5.12.5.4 Rescue centers & NGOs 85 5.12.5.5 Other end users 85 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86 6.1 TECHNOLOGY ANALYSIS 86 6.1.1 KEY EMERGING TECHNOLOGIES 86 6.1.1.1 Controlled release formulation 86 6.1.1.2 Biologics and monoclonal antibodies 86 6.1.2 COMPLEMENTARY TECHNOLOGIES 86 6.1.2.1 Digital health and telemedicine platforms 86 6.1.2.2 Veterinary biomarker analysis 87 6.1.3 ADJACENT TECHNOLOGIES 87 6.1.3.1 Wearable animal health monitoring devices 87 6.1.3.2 Stem cell therapy and regenerative medicine 87 6.2 TECHNOLOGY/PRODUCT ROADMAP 87 6.3 PATENT ANALYSIS 89 6.3.1 PUBLICATION TRENDS FOR VETERINARY PHARMACEUTICALS 89 6.3.2 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR VETERINARY PHARMACEUTICALS MARKET, JANUARY 2015–DECEMBER 2025 89 6.3.3 LIST OF MAJOR PATENTS, 2023–2025 91 6.4 FUTURE APPLICATIONS 92 6.4.1 PRECISION LIVESTOCK HEALTH MANAGEMENT 92 6.4.2 ONCOLOGY AND CHRONIC DISEASE MANAGEMENT 92 6.4.3 REPRODUCTIVE AND FERTILITY ENHANCEMENT IN LIVESTOCK 92 6.4.4 INTEGRATED DISEASE SURVEILLANCE AND OUTBREAK CONTROL 92 6.5 IMPACT OF GEN AI ON VETERINARY PHARMACEUTICALS MARKET 93 7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 94 7.1 REGIONAL REGULATIONS AND COMPLIANCE 94 7.1.1 REGULATORY FRAMEWORK 94 7.1.1.1 North America 94 7.1.1.2 Europe 95 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 7.1.3 INDUSTRY STANDARDS 99 7.1.3.1 VICH Guidelines (International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products) 99 7.1.3.2 Good Manufacturing Practice (GMP) Standards – PIC/S Guide (PE 009 series) 99 7.1.3.3 Codex Alimentarius Standards for Veterinary Drug Residues (CXM 2 – Maximum Residue Limits) 100 7.2 SUSTAINABILITY INITIATIVES 100 7.2.1 ECO-FRIENDLY AND RECYCLABLE MATERIALS IN VETERINARY PHARMACEUTICALS MARKET 100 7.2.1.1 Virbac – Eco-pack to reduce single-use plastic in veterinary products 100 7.2.1.2 Boehringer Ingelheim Animal Health – Renewable energy-powered manufacturing 100 7.2.1.3 Boehringer Ingelheim – Recyclable veterinary delivery device (Aservo, EquiHaler) 101 7.3 CERTIFICATIONS, LABELING, ECO-STANDARDS 101 8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 102 8.1 DECISION-MAKING PROCESS 102 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 103 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 103 8.2.2 BUYING CRITERIA 103 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 104 8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS 105 8.5 MARKET PROFITABILITY 106 8.5.1 PRODUCT INNOVATION AND DIFFERENTIATION 106 8.5.2 EXPANSION OF COMPANION ANIMAL HEALTHCARE SPENDING 106 8.5.3 OPERATIONAL SCALE AND DISTRIBUTION EFFICIENCY 106 9 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE 107 9.1 INTRODUCTION 108 9.1.1 VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 108 9.2 DRUGS 109 9.2.1 ANTI-BACTERIAL DRUGS 110 9.2.1.1 Routine use in livestock and companion animals underpins strong market share and steady growth 110 9.2.2 ANTI-FUNGAL DRUGS 112 9.2.2.1 Limited approvals and off-label systemic use result in smaller but clinically essential segment 112 9.2.3 ANTI-VIRAL DRUGS 113 9.2.3.1 Low current penetration but rising research interest driven by outbreak response and targeted therapies 113 9.2.4 ANTI-INFLAMMATORY DRUGS 114 9.2.4.1 Rising surgical volumes and chronic pain management drive stable double-digit market share 114 9.2.5 ANTI-PARASITIC DRUGS 115 9.2.5.1 High parasitic burden and preventive care practices sustain market share and strong growth trajectory 115 9.2.6 ANTI-CANCER DRUGS 116 9.2.6.1 Increasing pet oncology awareness and advanced therapeutics to fuel growth from small base 116 9.2.7 CARDIOVASCULAR AND RENAL DRUGS 117 9.2.7.1 Rising diagnosis of chronic heart and kidney disorders supports steady mid-single-digit market share 117 9.2.8 GASTROINTESTINAL DRUGS 118 9.2.8.1 High incidence of digestive disorders and dietary transitions drive sustained demand 118 9.2.9 OTHER DRUGS 119 9.3 MONOCLONAL ANTIBODIES 120 9.3.1 TARGETED BIOLOGICS AND RISING COMPANION ANIMAL THERAPEUTICS TO DRIVE DEMAND 120 9.4 IMMUNOMODULATORS 121 9.4.1 INCREASING FOCUS ON IMMUNE-MEDIATED DISEASES AND PREVENTIVE HEALTH TO SUPPORT GRADUAL EXPANSION FROM SMALLER BASE 121 9.5 MEDICATED FEED ADDITIVES 122 9.5.1 AMINO ACIDS 124 9.5.1.1 Protein optimization and feed cost efficiency to drive demand 124 9.5.2 ENZYMES 125 9.5.2.1 Improved nutrient digestibility and cost optimization to support steady adoption 125 9.5.3 VITAMINS AND MINERALS 126 9.5.3.1 Essential micronutrient supplementation ensures largest market share 126 9.5.4 OTHER MEDICATED FEED ADDITIVES 127 10 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION 128 10.1 INTRODUCTION 129 10.2 ORAL 129 10.2.1 EASE OF DOSING AND HIGH COMPLIANCE IN COMPANION AND LIVESTOCK ANIMALS 129   10.3 PARENTERAL 131 10.3.1 RAPID THERAPEUTIC ACTION AND HIGHER BIOAVAILABILITY IN CRITICAL CARE AND PRODUCTION SETTINGS 131 10.4 TOPICAL 132 10.4.1 RISING DERMATOLOGY CASES AND DEMAND FOR LOCALIZED, NON-INVASIVE TREATMENTS 132 10.5 OTHER ROUTES OF ADMINISTRATION 133 11 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE 134 11.1 INTRODUCTION 135 11.2 SOLID 135 11.2.1 DOSING STABILITY, COST EFFICIENCY, AND EASE OF LARGE-SCALE ADMINISTRATION IN LIVESTOCK AND COMPANION ANIMALS 135 11.3 LIQUID 137 11.3.1 RAPID ABSORPTION, FLEXIBLE DOSING, AND SUITABILITY FOR INJECTABLES AND ORAL SUSPENSIONS 137 11.4 SEMI-SOLID 138 11.4.1 RISING DERMATOLOGY CASES AND INCREASING COMPANION ANIMAL CARE EXPENDITURE 138 11.5 AEROSOL/SPRAY 139 11.5.1 CONVENIENCE, TARGETED DELIVERY, AND REDUCED CROSS-CONTAMINATION RISK 139 11.6 PREMIX FORMULATIONS 140 11.6.1 DEMAND FOR MEDICATED FEED AND PREVENTIVE HERD-LEVEL DISEASE MANAGEMENT TO DRIVE MARKET 140 12 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION 141 12.1 INTRODUCTION 142 12.2 INFECTIOUS DISEASES 142 12.2.1 ZOONOTIC RISK AND LIVESTOCK DISEASE CONTROL PROGRAMS TO DRIVE MARKET 142 12.3 DERMATOLOGICAL DISEASES 143 12.3.1 RISING CHRONIC SKIN CONDITIONS AND PREMIUM COMPANION ANIMAL SPENDING TO DRIVE MARKET 143 12.4 PAIN MANAGEMENT 145 12.4.1 RISING SURGICAL PROCEDURES AND AGING PET POPULATION TO DRIVE MARKET 145 12.5 CARDIOVASCULAR AND RENAL DISEASES 146 12.5.1 INCREASED DIAGNOSIS IN AGING COMPANION ANIMALS TO DRIVE MARKET 146 12.6 GASTROINTESTINAL DISEASES 147 12.6.1 HIGH PREVALENCE OF ENTERIC INFECTIONS AND DIETARY DISORDERS TO DRIVE MARKET 147 12.7 OTHER INDICATIONS 148   13 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE 149 13.1 INTRODUCTION 150 13.2 COMPANION ANIMALS 150 13.2.1 DOGS 153 13.2.1.1 Increasing population and adoption of dogs to drive market 153 13.2.2 CATS 155 13.2.2.1 Emerging trends in feline pharmaceuticals to boost market 155 13.2.3 HORSES 157 13.2.3.1 Higher risk of traumatic injuries in horses to drive demand for veterinary pharmaceutical products 157 13.2.4 OTHER COMPANION ANIMALS 158 13.3 LIVESTOCK ANIMALS 160 13.3.1 CATTLE 162 13.3.1.1 Economic importance of dairy and beef cattle to drive growth 162 13.3.2 SWINE 164 13.3.2.1 Growing surgical volume for acute conditions in swine to drive market 164 13.3.3 POULTRY 166 13.3.3.1 Growing focus on infection prevention and flock health management to drive market 166 13.3.4 OTHER LIVESTOCK ANIMALS 167 14 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL 169 14.1 INTRODUCTION 170 14.2 VETERINARY HOSPITAL PHARMACIES 170 14.2.1 HIGH IMPORTANCE AND BETTER OPPORTUNITIES IN ON-FARM VETERINARY PHARMACEUTICALS TO DRIVE MARKET 170 14.3 RETAIL PHARMACIES 172 14.3.1 RETAIL PHARMACIES TO AID ACCESSIBILITY AND MARKET REACH IN VETERINARY PHARMACEUTICALS 172 14.4 ONLINE PHARMACIES 174 14.4.1 CONVENIENCE AND ACCESSIBILITY TO AUGMENT MARKET GROWTH 174 14.5 DIRECT SALES 175 14.5.1 DIRECT SALES TO STRENGTHEN MANUFACTURER-TO-CUSTOMER CONNECTIONS 175 15 VETERINARY PHARMACEUTICALS MARKET, BY END USER 177 15.1 INTRODUCTION 178 15.2 VETERINARY HOSPITALS & CLINICS 178 15.2.1 FIRST POINT OF CONTACT FOR ANIMAL OWNERS AND LIVESTOCK CAREGIVERS 178 15.3 LIVESTOCK FARMS 180 15.3.1 GROWING IMPORTANCE AND OPPORTUNITIES IN ON-FARM ANIMAL CARE 180 15.4 HOME CARE SETTINGS 181 15.4.1 RISING PET EXPENDITURE TO PROPEL SEGMENT GROWTH 181 15.5 OTHER END USERS 182 16 VETERINARY PHARMACEUTICALS MARKET, BY REGION 183 16.1 INTRODUCTION 184 16.2 NORTH AMERICA 187 16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 187 16.2.2 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 190 16.2.3 US 195 16.2.3.1 Surge in animal healthcare expenditure to boost market 195 16.2.4 CANADA 201 16.2.4.1 Growing pet population and advanced veterinary services to drive market 201 16.3 EUROPE 207 16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 208 16.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 210 16.3.3 GERMANY 214 16.3.3.1 Increased focus on animal welfare to drive demand for veterinary pharmaceutical products 214 16.3.4 UK 220 16.3.4.1 Increasing pet ownership to propel market 220 16.3.5 FRANCE 226 16.3.5.1 High standards of veterinary care to provide attractive growth opportunities for market players 226 16.3.6 ITALY 233 16.3.6.1 Growing pet owner awareness and increasing livestock population to drive market 233 16.3.7 SPAIN 238 16.3.7.1 Increasing awareness of animal health to drive market 238 16.3.8 REST OF EUROPE 244 16.4 ASIA PACIFIC 249 16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 250 16.4.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 253 16.4.3 JAPAN 257 16.4.3.1 Surge in pet care expenditure and growing adoption of companion animals to drive market 257 16.4.4 CHINA 263 16.4.4.1 Increasing animal healthcare expenditure and advancements in veterinary medicines to drive market 263 16.4.5 INDIA 269 16.4.5.1 Increasing livestock population to propel market growth 269   16.4.6 AUSTRALIA 275 16.4.6.1 Growing companion animal ownership and rise in animal health awareness to support market growth 275 16.4.7 SOUTH KOREA 281 16.4.7.1 Growing pet ownership and advancements in veterinary medicine to favor market growth 281 16.4.8 PHILIPPINES 288 16.4.8.1 Tourism-linked pet culture and veterinary advancements to fuel market 288 16.4.9 REST OF ASIA PACIFIC 293 16.5 LATIN AMERICA 298 16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 299 16.5.2 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 300 16.5.3 BRAZIL 305 16.5.3.1 Growing pet population and rising disposable incomes to drive market 305 16.5.4 MEXICO 312 16.5.4.1 Robust livestock base and growing companion animal care to drive market 312 16.5.5 REST OF LATIN AMERICA 317 16.6 MIDDLE EAST & AFRICA 322 16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 323 16.6.2 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 324 16.7 GCC COUNTRIES 328 16.7.1 KINGDOM OF SAUDI ARABIA (KSA) 335 16.7.1.1 Vision 2030 investments to drive market 335 16.7.2 UNITED ARAB EMIRATES (UAE) 341 16.7.2.1 Increasing adoption of advanced diagnostic technologies to contribute to market growth 341 16.7.3 REST OF GCC COUNTRIES 346 16.7.4 REST OF MIDDLE EAST & AFRICA 351 17 COMPETITIVE LANDSCAPE 357 17.1 INTRODUCTION 357 17.1.1 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026 357 17.2 REVENUE ANALYSIS, 2023–2025 358 17.3 MARKET SHARE ANALYSIS, 2025 359 17.3.1 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 361 17.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 362 17.4 PRODUCT/BRAND COMPARISON 363 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 364 17.5.1 STARS 364 17.5.2 EMERGING LEADERS 364 17.5.3 PERVASIVE PLAYERS 364 17.5.4 PARTICIPANTS 364 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 366 17.5.5.1 Company footprint 366 17.5.5.2 Region footprint 367 17.5.5.3 Product type footprint 368 17.5.5.4 Route of administration footprint 369 17.5.5.5 Indication footprint 370 17.5.5.6 End user footprint 371 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 372 17.6.1 PROGRESSIVE COMPANIES 372 17.6.2 RESPONSIVE COMPANIES 372 17.6.3 DYNAMIC COMPANIES 372 17.6.4 STARTING BLOCKS 372 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 374 17.6.5.1 Detailed list of key startups/SMEs 374 17.6.5.2 Competitive benchmarking of key startups/SMEs 375 17.7 COMPANY VALUATION AND FINANCIAL METRICS 376 17.8 COMPETITIVE SCENARIO 376 17.8.1 PRODUCT LAUNCHES & APPROVALS 377 17.8.2 DEALS 378 17.8.3 EXPANSIONS 379 17.8.4 OTHER DEVELOPMENTS 379 18 COMPANY PROFILES 380 18.1 KEY PLAYERS 380 18.1.1 ZOETIS INC. 380 18.1.1.1 Business overview 380 18.1.1.2 Products offered 382 18.1.1.3 Recent developments 383 18.1.1.3.1 Product launches & approvals 383 18.1.1.3.2 Expansions 384 18.1.1.3.3 Other developments 384 18.1.1.4 MnM view 385 18.1.1.4.1 Right to win 385 18.1.1.4.2 Strategic choices 385 18.1.1.4.3 Weaknesses and competitive threats 385 18.1.2 MERCK & CO., INC 386 18.1.2.1 Business overview 386 18.1.2.2 Products offered 387 18.1.2.3 Recent developments 388 18.1.2.3.1 Product launches & approvals 388 18.1.2.3.2 Deals 389 18.1.2.3.3 Expansions 390 18.1.2.4 MnM view 390 18.1.2.4.1 Right to win 390 18.1.2.4.2 Strategic choices 391 18.1.2.4.3 Weaknesses and competitive threats 391 18.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 392 18.1.3.1 Business overview 392 18.1.3.2 Products offered 393 18.1.3.3 Recent developments 394 18.1.3.3.1 Product launches & approvals 394 18.1.3.3.2 Deals 395 18.1.3.3.3 Expansions 396 18.1.3.4 MnM view 397 18.1.3.4.1 Right to win 397 18.1.3.4.2 Strategic choices 397 18.1.3.4.3 Weaknesses and competitive threats 397 18.1.4 ELANCO ANIMAL HEALTH INCORPORATED 398 18.1.4.1 Business overview 398 18.1.4.2 Products offered 399 18.1.4.3 Recent developments 401 18.1.4.3.1 Product launches & approvals 401 18.1.4.3.2 Expansions 402 18.1.4.3.3 Other developments 403 18.1.4.4 MnM view 403 18.1.4.4.1 Right to win 403 18.1.4.4.2 Strategic choices 403 18.1.4.4.3 Weaknesses and competitive threats 403 18.1.5 VIRBAC 404 18.1.5.1 Business overview 404 18.1.5.2 Products offered 405 18.1.5.3 Recent developments 406 18.1.5.3.1 Product launches & approvals 406 18.1.5.3.2 Deal 407 18.1.5.3.3 Expansions 408 18.1.5.4 MnM view 408 18.1.5.4.1 Right to win 408 18.1.5.4.2 Strategic choices 408 18.1.5.4.3 Weaknesses and competitive threats 408   18.1.6 CEVA 409 18.1.6.1 Business overview 409 18.1.6.2 Products offered 410 18.1.6.3 Recent developments 410 18.1.6.3.1 Deals 410 18.1.6.3.2 Expansions 411 18.1.7 VETOQUINOL 412 18.1.7.1 Business overview 412 18.1.7.2 Products offered 413 18.1.7.3 Recent developments 415 18.1.7.3.1 Product launches & approvals 415 18.1.7.3.2 Deals 415 18.1.8 DECHRA PHARMACEUTICALS PLC 416 18.1.8.1 Business overview 416 18.1.8.2 Products offered 416 18.1.8.3 Recent developments 418 18.1.8.3.1 Product launches & approvals 418 18.1.8.3.2 Deals 419 18.1.8.3.3 Other developments 419 18.1.9 NORBROOK 420 18.1.9.1 Business overview 420 18.1.9.2 Products offered 420 18.1.9.3 Recent developments 423 18.1.9.3.1 Product launches & approvals 423 18.1.9.3.2 Deals 423 18.1.9.3.3 Expansions 424 18.1.9.3.4 Other developments 424 18.1.10 BIMEDA CORPORATE 425 18.1.10.1 Business overview 425 18.1.10.2 Products offered 425 18.1.10.3 Recent developments 427 18.1.10.3.1 Product launches & approvals 427 18.1.10.3.2 Deals 428 18.1.10.3.3 Expansions 428 18.1.11 HESTER BIOSCIENCES LIMITED 429 18.1.11.1 Business overview 429 18.1.11.2 Products offered 430 18.1.12 INDIAN IMMUNOLOGICALS LTD. 432 18.1.12.1 Business overview 432 18.1.12.2 Products offered 433   18.1.13 ANIMALCARE GROUP PLC 435 18.1.13.1 Business overview 435 18.1.13.2 Products offered 437 18.1.13.3 Recent developments 438 18.1.13.3.1 Deals 438 18.1.13.3.2 Product launches & approvals 439 18.1.14 KYORITSU SEIYAKU CORPORATION 440 18.1.14.1 Business overview 440 18.1.14.2 Products offered 440 18.1.14.3 Recent developments 442 18.1.14.3.1 Product launches & approvals 442 18.1.14.3.2 Deals 443 18.1.15 CALIER 444 18.1.15.1 Business overview 444 18.1.15.2 Products offered 444 18.1.15.3 Recent developments 446 18.1.15.3.1 Product launches & approvals 446 18.2 OTHER PLAYERS 447 18.2.1 DOPHARMA 447 18.2.2 PHARMGATE ANIMAL HEALTH 448 18.2.3 BIOVETA, A.S. 449 18.2.4 NEXTMUNE 450 18.2.5 TRIVIUMVET 451 18.2.6 DOMES PHARMA 452 18.2.7 UNIVET LIMITED 453 18.2.8 CENAVISA, S.L. 454 18.2.9 FATRO S.P.A. 455 18.2.10 CHANELLE PHARMA 456 19 RESEARCH METHODOLOGY 457 19.1 RESEARCH DATA 457 19.1.1 SECONDARY DATA 458 19.1.1.1 Key data from secondary sources 459 19.1.2 PRIMARY DATA 460 19.1.2.1 Key data from primary sources 461 19.1.2.2 Key industry insights 461 19.1.2.3 Key industry insights 462 19.2 MARKET SIZE ESTIMATION 462 19.3 GROWTH FORECAST 466 19.3.1 KEY INDUSTRY INSIGHTS 468 19.4 MARKET BREAKDOWN AND DATA TRIANGULATION 469   19.5 RESEARCH ASSUMPTIONS 470 19.6 RESEARCH LIMITATIONS 470 19.7 RISK ASSESSMENT 470 20 APPENDIX 471 20.1 DISCUSSION GUIDE 471 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 478 20.3 CUSTOMIZATION OPTIONS 480 20.3.1 PRODUCT ANALYSIS 480 20.3.2 US END USER ANALYSIS 480 20.3.3 GEOGRAPHIC ANALYSIS 480 20.3.4 COMPANY INFORMATION 480 20.3.5 REGIONAL/COUNTRY LEVEL MARKET SHARE ANALYSIS 480 20.3.6 COUNTRY LEVEL VOLUME ANALYSIS BY PRODUCT TYPE 480 20.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 480 20.3.8 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 480 20.4 RELATED REPORTS 481 20.5 AUTHOR DETAILS 482

TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD) 43 TABLE 2 PET (DOGS AND CATS) OWNERSHIP STATISTICS IN US, 2024 55 TABLE 3 COMPANION ANIMAL POPULATION STATISTICS, BY REGION 55 TABLE 4 RECENT GOVERNMENT-REPORTED INDICATORS 57 TABLE 5 TRENDS IN CONSUMPTION OF MEAT & MILK IN DEVELOPED & EMERGING ECONOMIES 57 TABLE 6 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 58 TABLE 7 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 58 TABLE 8 UNMET CUSTOMER NEEDS AND WHITE SPACES IN VETERINARY PHARMACEUTICALS MARKET. 62 TABLE 9 INTERCONNECTED MARKETS IN VETERINARY PHARMACEUTICALS MARKET 63 TABLE 10 CROSS-SECTOR MARKETS IN VETERINARY PHARMACEUTICALS MARKET 64 TABLE 11 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64 TABLE 12 IMPACT OF PORTER’S FIVE FORCES ON VETERINARY PHARMACEUTICALS MARKET 66 TABLE 13 GDP TREND AND FORECAST, BY COUNTRY, 2021–2030 (USD BILLION) 67 TABLE 14 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025 74 TABLE 15 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025 75 TABLE 16 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 76 TABLE 17 IMPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION) 77 TABLE 18 EXPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION) 78 TABLE 19 DETAILED LIST OF CONFERENCES AND EVENTS, 2026–2027 78 TABLE 20 US ADJUSTED RECIPROCAL TARIFF RATES 83 TABLE 21 TECHNOLOGY/PRODUCT ROADMAP 88 TABLE 22 VETERINARY PHARMACEUTICALS MARKET: LIST OF MAJOR PATENTS, JANUARY 2023–DECEMBER 2025 91 TABLE 23 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 TABLE 24 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 25 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS 103 TABLE 28 KEY BUYING CRITERIA FOR TOP THREE END USERS 104 TABLE 29 VETERINARY PHARMACEUTICALS MARKET: UNMET NEEDS IN KEY END-USE SETTINGS 106 TABLE 30 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 108 TABLE 31 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 108 TABLE 32 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 109 TABLE 33 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 110 TABLE 34 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-BACTERIAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 111 TABLE 35 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-FUNGAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 112 TABLE 36 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-VIRAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 113 TABLE 37 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 114 TABLE 38 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-PARASITIC DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 115 TABLE 39 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-CANCER DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 116 TABLE 40 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 117 TABLE 41 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 118 TABLE 42 VETERINARY PHARMACEUTICALS MARKET FOR OTHER DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 119 TABLE 43 VETERINARY PHARMACEUTICALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 120 TABLE 44 VETERINARY PHARMACEUTICALS MARKET FOR IMMUNOMODULATORS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 121 TABLE 45 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 122 TABLE 46 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 123 TABLE 47 VETERINARY PHARMACEUTICALS MARKET FOR AMINO ACIDS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 124 TABLE 48 VETERINARY PHARMACEUTICALS MARKET FOR ENZYMES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 125 TABLE 49 VETERINARY PHARMACEUTICALS MARKET FOR VITAMINS AND MINERALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 126 TABLE 50 VETERINARY PHARMACEUTICALS MARKET FOR OTHER MEDICATED FEED ADDITIVES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 127 TABLE 51 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 129 TABLE 52 VETERINARY PHARMACEUTICALS MARKET FOR ORAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 130 TABLE 53 VETERINARY PHARMACEUTICALS MARKET FOR PARENTERAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 131 TABLE 54 VETERINARY PHARMACEUTICALS MARKET FOR TOPICAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 132 TABLE 55 VETERINARY PHARMACEUTICALS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 133 TABLE 56 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 135 TABLE 57 VETERINARY PHARMACEUTICALS MARKET FOR SOLID, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 136 TABLE 58 VETERINARY PHARMACEUTICALS MARKET FOR LIQUID, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 137 TABLE 59 VETERINARY PHARMACEUTICALS MARKET FOR SEMI-SOLID, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 138 TABLE 60 VETERINARY PHARMACEUTICALS MARKET FOR AEROSOL/SPRAY, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 139 TABLE 61 VETERINARY PHARMACEUTICALS MARKET FOR PREMIX FORMULATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 140 TABLE 62 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 142 TABLE 63 VETERINARY PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 143 TABLE 64 VETERINARY PHARMACEUTICALS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 144 TABLE 65 VETERINARY PHARMACEUTICALS MARKET FOR PAIN MANAGEMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 145 TABLE 66 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 146 TABLE 67 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 147 TABLE 68 VETERINARY PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 148 TABLE 69 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 150 TABLE 70 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 151 TABLE 71 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 152 TABLE 72 VETERINARY PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 154 TABLE 73 VETERINARY PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 156 TABLE 74 VETERINARY PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 158 TABLE 75 VETERINARY PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 159 TABLE 76 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 160 TABLE 77 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 161 TABLE 78 VETERINARY PHARMACEUTICALS MARKET FOR CATTLE, BY COUNTRY/ REGION, 2024–2031 (USD MILLION) 163 TABLE 79 VETERINARY PHARMACEUTICALS MARKET FOR SWINE, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 165 TABLE 80 VETERINARY PHARMACEUTICALS MARKET FOR POULTRY, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 167 TABLE 81 VETERINARY PHARMACEUTICALS MARKET FOR OTHER LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 168 TABLE 82 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 170 TABLE 83 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITAL PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 171 TABLE 84 VETERINARY PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 173 TABLE 85 VETERINARY PHARMACEUTICALS MARKET FOR ONLINE PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 175 TABLE 86 VETERINARY PHARMACEUTICALS MARKET FOR DIRECT SALES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 176 TABLE 87 VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 178 TABLE 88 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 89 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK FARMS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 180 TABLE 90 VETERINARY PHARMACEUTICALS MARKET FOR HOME CARE SETTINGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 181 TABLE 91 VETERINARY PHARMACEUTICALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 92 VETERINARY PHARMACEUTICALS MARKET, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 93 VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 186 TABLE 94 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 95 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 190 TABLE 96 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 190 TABLE 97 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 98 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 99 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 192 TABLE 100 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 192 TABLE 101 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 193 TABLE 102 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 193 TABLE 103 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 104 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 105 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 195 TABLE 106 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 195 TABLE 107 US: KEY MACRO INDICATORS 196 TABLE 108 US: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 197 TABLE 109 US: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 110 US: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 111 US: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 198 TABLE 112 US: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 199 TABLE 113 US: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 199 TABLE 114 US: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 200 TABLE 115 US: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 116 US: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 117 US: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 201 TABLE 118 US: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 201 TABLE 119 CANADA: KEY MACRO INDICATORS 202 TABLE 120 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 202 TABLE 121 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 122 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 123 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 204 TABLE 124 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 204 TABLE 125 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 205 TABLE 126 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 205 TABLE 127 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 128 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 129 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 207 TABLE 130 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 207 TABLE 131 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 132 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 209 TABLE 133 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 210 TABLE 134 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 135 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 136 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 211 TABLE 137 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 212 TABLE 138 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 212 TABLE 139 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 213 TABLE 140 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 141 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 142 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 214 TABLE 143 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 214 TABLE 144 GERMANY: KEY MACRO INDICATORS 215 TABLE 145 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 215 TABLE 146 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 147 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 148 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 217 TABLE 149 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 217 TABLE 150 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 218 TABLE 151 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 218 TABLE 152 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 153 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 154 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 220 TABLE 155 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 220 TABLE 156 UK: KEY MACRO INDICATORS 221 TABLE 157 UK: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 221 TABLE 158 UK: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 159 UK: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 160 UK: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 223 TABLE 161 UK: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 223 TABLE 162 UK: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 224 TABLE 163 UK: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 224 TABLE 164 UK: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 165 UK: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 166 UK: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 226 TABLE 167 UK: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 226 TABLE 168 FRANCE: KEY MACRO INDICATORS 227 TABLE 169 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 227 TABLE 170 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 171 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 172 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 229 TABLE 173 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 229 TABLE 174 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 230 TABLE 175 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 230 TABLE 176 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 177 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 178 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 232 TABLE 179 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 232 TABLE 180 ITALY: KEY MACRO INDICATORS 233 TABLE 181 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 233 TABLE 182 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 183 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 184 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 235 TABLE 185 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 235 TABLE 186 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 236 TABLE 187 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 236 TABLE 188 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 189 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 190 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 238 TABLE 191 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 238 TABLE 192 SPAIN: KEY MACRO INDICATORS 239 TABLE 193 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 239 TABLE 194 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 195 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 196 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 241 TABLE 197 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 241 TABLE 198 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 242 TABLE 199 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 242 TABLE 200 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 201 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 202 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 244 TABLE 203 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 244 TABLE 204 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 245 TABLE 205 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 206 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 207 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 246 TABLE 208 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 247 TABLE 209 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 247 TABLE 210 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 248 TABLE 211 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 212 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 213 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 249 TABLE 214 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 249 TABLE 215 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 252 TABLE 216 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 252 TABLE 217 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 253 TABLE 218 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 219 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 220 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 254 TABLE 221 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 255 TABLE 222 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 255 TABLE 223 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 256 TABLE 224 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 225 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 226 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 257 TABLE 227 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 228 JAPAN: KEY MACRO INDICATORS 258 TABLE 229 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 258 TABLE 230 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 231 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 232 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 260 TABLE 233 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 260 TABLE 234 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 261 TABLE 235 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 261 TABLE 236 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 237 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 238 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 263 TABLE 239 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 263 TABLE 240 CHINA: KEY MACRO INDICATORS 264 TABLE 241 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 264 TABLE 242 CHINA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 243 CHINA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 244 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 266 TABLE 245 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 266 TABLE 246 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 267 TABLE 247 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 267 TABLE 248 CHINA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 249 CHINA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 250 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 269 TABLE 251 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 269 TABLE 252 INDIA: KEY MACRO INDICATORS 270 TABLE 253 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 270 TABLE 254 INDIA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 255 INDIA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 256 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 272 TABLE 257 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 272 TABLE 258 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 273 TABLE 259 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 273 TABLE 260 INDIA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 261 INDIA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 262 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 275 TABLE 263 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 275 TABLE 264 AUSTRALIA: KEY MACRO INDICATORS 276 TABLE 265 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 276 TABLE 266 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 267 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 268 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 278 TABLE 269 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 278 TABLE 270 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 279 TABLE 271 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 279 TABLE 272 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 273 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 274 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 281 TABLE 275 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 281 TABLE 276 SOUTH KOREA: KEY MACRO INDICATORS 282 TABLE 277 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 282 TABLE 278 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 279 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 280 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 284 TABLE 281 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 284 TABLE 282 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 285 TABLE 283 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 285 TABLE 284 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 285 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 286 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 287 TABLE 287 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 287 TABLE 288 PHILIPPINES: KEY MACRO INDICATORS 288 TABLE 289 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 288 TABLE 290 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 291 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 292 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 290 TABLE 293 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 290 TABLE 294 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 291 TABLE 295 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 291 TABLE 296 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 297 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 298 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 293 TABLE 299 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 293 TABLE 300 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 294 TABLE 301 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 302 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 303 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 295 TABLE 304 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 296 TABLE 305 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 296 TABLE 306 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 297 TABLE 307 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 308 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 309 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 298 TABLE 310 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 298 TABLE 311 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 299 TABLE 312 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 300 TABLE 313 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 300 TABLE 314 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 315 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 316 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 302 TABLE 317 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 302 TABLE 318 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 303 TABLE 319 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 303 TABLE 320 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 321 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 322 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 305 TABLE 323 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 305 TABLE 324 BRAZIL: KEY MACRO INDICATORS 306 TABLE 325 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 306 TABLE 326 BRAZIL: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 327 BRAZIL: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 328 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 308 TABLE 329 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 308 TABLE 330 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 309 TABLE 331 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 309 TABLE 332 BRAZIL: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 333 BRAZIL: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 334 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 311 TABLE 335 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 311 TABLE 336 MEXICO: KEY MACRO INDICATORS 312 TABLE 337 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 312 TABLE 338 MEXICO: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 339 MEXICO: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 340 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 314 TABLE 341 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 314 TABLE 342 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 315 TABLE 343 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 315 TABLE 344 MEXICO: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 345 MEXICO: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 346 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 317 TABLE 347 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 317 TABLE 348 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 318 TABLE 349 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 350 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 351 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 319 TABLE 352 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 320 TABLE 353 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 320 TABLE 354 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 321 TABLE 355 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 356 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 357 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 322 TABLE 358 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 322 TABLE 359 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 323 TABLE 360 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 323 TABLE 361 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 324 TABLE 362 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 363 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 364 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 325 TABLE 365 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 326 TABLE 366 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 326 TABLE 367 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 327 TABLE 368 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 369 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 370 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 328 TABLE 371 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 328 TABLE 372 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 329 TABLE 373 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 329 TABLE 374 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 375 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 376 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 331 TABLE 377 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 331 TABLE 378 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 332 TABLE 379 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 332 TABLE 380 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 381 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 382 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 334 TABLE 383 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 334 TABLE 384 KINGDOM OF SAUDI ARABIA (KSA): KEY MACRO INDICATORS 335 TABLE 385 KSA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 335 TABLE 386 KSA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 387 KSA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 388 KSA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 337 TABLE 389 KSA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 337 TABLE 390 KSA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 338 TABLE 391 KSA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 338 TABLE 392 KSA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 393 KSA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 394 KSA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 340 TABLE 395 KSA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 340 TABLE 396 UNITED ARAB EMIRATES (UAE): KEY MACRO INDICATORS 341 TABLE 397 UAE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 341 TABLE 398 UAE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 399 UAE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 400 UAE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 343 TABLE 401 UAE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 343 TABLE 402 UAE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 344 TABLE 403 UAE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 344 TABLE 404 UAE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 405 UAE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 406 UAE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 346 TABLE 407 UAE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 346 TABLE 408 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 347 TABLE 409 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 347 TABLE 410 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 411 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 348 TABLE 412 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 349 TABLE 413 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 349 TABLE 414 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 350 TABLE 415 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 416 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 417 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 351 TABLE 418 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 351 TABLE 419 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 352 TABLE 420 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 352 TABLE 421 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 353 TABLE 422 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 353 TABLE 423 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 354 TABLE 424 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 354 TABLE 425 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 355 TABLE 426 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 427 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 428 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 356 TABLE 429 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 356 TABLE 430 VETERINARY PHARMACEUTICALS MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2023–2026 357 TABLE 431 VETERINARY PHARMACEUTICALS MARKET: DEGREE OF COMPETITION 360 TABLE 432 VETERINARY PHARMACEUTICALS MARKET: REGION FOOTPRINT 367 TABLE 433 VETERINARY PHARMACEUTICALS MARKET: PRODUCT TYPE FOOTPRINT 368 TABLE 434 VETERINARY PHARMACEUTICALS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 369 TABLE 435 VETERINARY PHARMACEUTICALS MARKET: INDICATION FOOTPRINT 370 TABLE 436 VETERINARY PHARMACEUTICALS MARKET: END USER FOOTPRINT 371 TABLE 437 VETERINARY PHARMACEUTICALS MARKET: KEY STARTUPS/SMES 374 TABLE 438 VETERINARY PHARMACEUTICALS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 375 TABLE 439 VETERINARY PHARMACEUTICALS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JANUARY 2026 377 TABLE 440 VETERINARY PHARMACEUTICALS MARKET: DEALS, JANUARY 2023–JANUARY 2026 378 TABLE 441 VETERINARY PHARMACEUTICALS MARKET: EXPANSIONS, JANUARY 2023–JANUARY 2026 379 TABLE 442 VETERINARY PHARMACEUTICALS MARKET: OTHER DEVELOPMENTS, JANUARY 2023–JANUARY 2026 379 TABLE 443 ZOETIS INC.: COMPANY OVERVIEW 380 TABLE 444 ZOETIS INC.: PRODUCTS OFFERED 382 TABLE 445 ZOETIS, INC.: PRODUCT LAUNCHES & APPROVALS 383 TABLE 446 ZOETIS, INC.: EXPANSIONS 384 TABLE 447 ZOETIS, INC.: OTHER DEVELOPMENTS 384 TABLE 448 MERCK & CO., INC.: COMPANY OVERVIEW 386 TABLE 449 MERCK & CO., INC.: PRODUCTS OFFERED 387 TABLE 450 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS 388 TABLE 451 MERCK & CO., INC.: DEALS 389 TABLE 452 MERCK & CO., INC.: EXPANSIONS 390 TABLE 453 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 392 TABLE 454 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 393 TABLE 455 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT LAUNCHES & APPROVALS 394 TABLE 456 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS 395 TABLE 457 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS 396 TABLE 458 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY OVERVIEW 398 TABLE 459 ELANCO ANIMAL HEALTH INCORPORATED: PRODUCTS OFFERED 399 TABLE 460 ELANCO ANIMAL HEALTH INCORPORATED: PRODUCT LAUNCHES & APPROVALS 401 TABLE 461 ELANCO ANIMAL HEALTH INCORPORATED: EXPANSIONS 402 TABLE 462 ELANCO ANIMAL HEALTH INCORPORATED: OTHER DEVELOPMENTS 403 TABLE 463 VIRBAC: COMPANY OVERVIEW 404 TABLE 464 VIRBAC: PRODUCTS OFFERED 405 TABLE 465 VIRBAC: PRODUCT LAUNCHES & APPROVALS 406 TABLE 466 VIRBAC: DEALS 407 TABLE 467 VIRBAC: EXPANSIONS 408 TABLE 468 CEVA: COMPANY OVERVIEW 409 TABLE 469 CEVA: PRODUCTS OFFERED 410 TABLE 470 CEVA: DEALS 410 TABLE 471 CEVA: EXPANSIONS 411 TABLE 472 VETOQUINOL: COMPANY OVERVIEW 412 TABLE 473 VETOQUINOL: PRODUCTS OFFERED 413 TABLE 474 VETOQUINOL: PRODUCT LAUNCHES & APPROVALS 415 TABLE 475 VETOQUINOL: DEALS 415 TABLE 476 DECHRA PHARMACEUTICALS PLC: COMPANY OVERVIEW 416 TABLE 477 DECHRA PHARMACEUTICALS PLC: PRODUCTS OFFERED 416 TABLE 478 DECHRA PHARMACEUTICALS PLC: PRODUCT LAUNCHES & APPROVALS 418 TABLE 479 DECHRA PHARMACEUTICALS PLC: DEALS 419 TABLE 480 DECHRA PHARMACEUTICALS PLC: OTHER DEVELOPMENTS 419 TABLE 481 NORBROOK: COMPANY OVERVIEW 420 TABLE 482 NORBROOK: PRODUCTS OFFERED 420 TABLE 483 NORBROOK: PRODUCT LAUNCHES & APPROVALS 423 TABLE 484 NORBROOK: DEALS 423 TABLE 485 NORBROOK: EXPANSIONS 424 TABLE 486 NORBROOK: OTHER DEVELOPMENTS 424 TABLE 487 BIMEDA CORPORATE: COMPANY OVERVIEW 425 TABLE 488 BIMEDA CORPORATE: PRODUCTS OFFERED 425 TABLE 489 BIMEDA CORPORATE: PRODUCT LAUNCHES & APPROVALS 427 TABLE 490 BIMEDA CORPORATE: DEALS 428 TABLE 491 BIMEDA CORPORATE: EXPANSIONS 428 TABLE 492 HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW 429 TABLE 493 HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED 430 TABLE 494 INDIAN IMMUNOLOGICALS LTD.: COMPANY OVERVIEW 432 TABLE 495 INDIAN IMMUNOLOGICALS LTD.: PRODUCTS OFFERED 433 TABLE 496 ANIMALCARE GROUP PLC: COMPANY OVERVIEW 435 TABLE 497 ANIMALCARE GROUP PLC: PRODUCTS OFFERED 437 TABLE 498 ANIMALCARE GROUP PLC.: DEALS 438 TABLE 499 ANIMALCARE GROUP PLC: PRODUCT LAUNCHES & APPROVALS 439 TABLE 500 KYORITSU SEIYAKU CORPORATION: COMPANY OVERVIEW 440 TABLE 501 KYORITSU SEIYAKU CORPORATION: PRODUCTS OFFERED 440 TABLE 502 KYORITSU SEIYAKU CORPORATION: PRODUCT LAUNCHES & APPROVALS 442 TABLE 503 KYORITSU SEIYAKU CORPORATION: DEALS 443 TABLE 504 CALIER: COMPANY OVERVIEW 444 TABLE 505 CALIER: PRODUCTS OFFERED 444 TABLE 506 CALIER: PRODUCT LAUNCHES & APPROVALS 446 FIGURE 1 VETERINARY PHARMACEUTICALS MARKET SEGMENTATION 42 FIGURE 2 MARKET SCENARIO 45 FIGURE 3 VETERINARY PHARMACEUTICALS MARKET, 2024–2031 46 FIGURE 4 VETERINARY PHARMACEUTICALS MARKET: MAJOR STRATEGIES ADOPTED BY KEY PLAYERS, 2022–2025 46 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VETERINARY PHARMACEUTICALS MARKET 47 FIGURE 6 VETERINARY PHARMACEUTICALS MARKET: HIGH-GROWTH SEGMENTS, 2026–2031 48 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 49 FIGURE 8 INCREASING PET CARE EXPENDITURE TO DRIVE MARKET 50 FIGURE 9 DRUGS SEGMENT AND CHINA DOMINATED MARKET IN 2025 51 FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 52 FIGURE 11 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 52 FIGURE 12 VETERINARY PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53 FIGURE 13 PET POPULATION IN MAJOR MARKETS, 2022 (MILLION) 54 FIGURE 14 EUROPE: PET POPULATION, 2021–2023 56 FIGURE 15 VETERINARY PHARMACEUTICALS MARKET: PORTER’S FIVE FORCES ANALYSIS 65 FIGURE 16 VETERINARY PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS 71 FIGURE 17 VETERINARY PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS 72 FIGURE 18 VETERINARY PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS 73 FIGURE 19 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79 FIGURE 20 INVESTMENT/VENTURE CAPITAL SCENARIO IN VETERINARY PHARMACEUTICALS MARKET, 2021–2025 80 FIGURE 21 PATENTS APPLIED AND GRANTED, JANUARY 2015–DECEMBER 2025 90 FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY PHARMACEUTICALS PRODUCTS, JANUARY 2015–DECEMBER 2025 91 FIGURE 23 VETERINARY PHARMACEUTICALS MARKET: DECISION-MAKING FACTORS 102 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS 103 FIGURE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS 104 FIGURE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES 105 FIGURE 27 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT 184 FIGURE 28 NORTH AMERICA: EXPECTED GROWTH IN NUMBER OF VETERINARIANS, 2020–2030 188 FIGURE 29 NORTH AMERICA: PET POPULATION, 2024 (MILLION) 188 FIGURE 30 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT 189 FIGURE 31 US: TOTAL PET HEALTH EXPENDITURE, 2020–2024 196 FIGURE 32 EUROPE: PET POPULATION, 2023 (MILLION) 208 FIGURE 33 ASIA PACIFIC: DOG POPULATION, BY COUNTRY, 2024 250 FIGURE 34 ASIA PACIFIC: CAT POPULATION, BY COUNTRY, 2024 251 FIGURE 35 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT 251 FIGURE 36 VETERINARY PHARMACEUTICALS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2023−2025 359 FIGURE 37 VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 360 FIGURE 38 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 361 FIGURE 39 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 362 FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS 363 FIGURE 41 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 365 FIGURE 42 VETERINARY PHARMACEUTICALS MARKET: COMPANY FOOTPRINT 366 FIGURE 43 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 373 FIGURE 44 EV/EBITDA OF KEY VENDORS 376 FIGURE 45 5-YEAR STOCK BETA OF KEY VENDORS 376 FIGURE 46 ZOETIS INC.: COMPANY SNAPSHOT (2025) 381 FIGURE 47 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 387 FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025) 393 FIGURE 49 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2025) 399 FIGURE 50 VIRBAC: COMPANY SNAPSHOT (2025) 405 FIGURE 51 CEVA: COMPANY SNAPSHOT (2025) 409 FIGURE 52 VETOQUINOL: COMPANY SNAPSHOT (2025) 413 FIGURE 53 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT (2025) 430 FIGURE 54 INDIAN IMMUNOLOGICALS LTD.: COMPANY SNAPSHOT (2025) 432 FIGURE 55 ANIMALCARE GROUP PLC: COMPANY SNAPSHOT 436 FIGURE 56 RESEARCH DESIGN 457 FIGURE 57 PRIMARY SOURCES 460 FIGURE 58 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS 461 FIGURE 59 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS 462 FIGURE 60 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 462 FIGURE 61 MARKET SIZE ESTIMATION APPROACH: REVENUE SHARE ANALYSIS 463 FIGURE 62 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025) 463 FIGURE 63 VETERINARY PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS 464 FIGURE 64 TOP-DOWN APPROACH 465 FIGURE 65 VETERINARY PHARMACEUTICALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031) 466 FIGURE 66 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF VETERINARY PHARMACEUTICALS MARKET (2026-2031) 467 FIGURE 67 DATA TRIANGULATION 469